The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study

Aliment Pharmacol Ther. 2018 Nov;48(9):941-950. doi: 10.1111/apt.14969. Epub 2018 Sep 18.

Abstract

Background: Treatment paradigms for Crohn's disease with perianal fistulae (CD-pAF) are evolving.

Aims: To study the impact of multimodality treatment in CD-pAF on recurrence rates and the need for re-interventions and to identify predictive factors for these outcomes.

Methods: This was a multinational multicentre retrospective cohort study. Multimodality approach was defined as using a combination of medical treatments (anti-TNFs ± immunomodulators ± antibiotics) along with surgical approach (examination under anaesthesia (EUA) ± seton drainage) at diagnosis of CD-pAF. Univariable and multivariable analyses were performed for variables indicative of the need for reintervention.

Results: A total of 253 patients were included. 65% of patients received multimodality approach. Multimodality treatment resulted in complete fistula healing in 52% of patients. Re-intervention was needed in 27% of patients with simple and in 40.3% of those with complex fistula. On multivariable analysis multimodality treatment (OR: 0.35, 95% CI: 0.17-0.57, P = 0.001), seton removal (OR: 0.090, 95% CI: 0.027-0.30, P = 0.0001, therapy with infliximab (OR: 0.19, 95% CI: 0.06-0.64, P = 0.007), and therapy with adalimumab (OR: 0.12, "95% CI: 0.026-0.56, P = 0.007) were predictive of avoiding repeat surgery. Proctitis (OR: 3.76, 95% CI: 1.09-12.96, P = 0.03) was predictive of the need for radical surgery (proctectomy, diverting stoma) while multimodality treatment reduced the need for radical surgery (OR: 0.21, 95% CI: 0.05-0.81, P = 0.02).

Conclusions: Multimodality treatment, anti-TNFs use, and removal of setons after multimodality treatment can result in improved outcomes in CD patients with perianal fistulae and reduce the need for repeat surgery and radical surgery.

Publication types

  • Multicenter Study

MeSH terms

  • Adalimumab / pharmacology
  • Adalimumab / therapeutic use
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Cohort Studies
  • Combined Modality Therapy / methods
  • Crohn Disease / drug therapy*
  • Crohn Disease / epidemiology
  • Crohn Disease / surgery*
  • Drainage / methods
  • Female
  • Gastrointestinal Agents / pharmacology
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Infliximab / pharmacology
  • Infliximab / therapeutic use
  • Internationality
  • Male
  • Middle Aged
  • Rectal Fistula / drug therapy*
  • Rectal Fistula / epidemiology
  • Rectal Fistula / surgery*
  • Retrospective Studies
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Wound Healing / drug effects
  • Wound Healing / physiology
  • Young Adult

Substances

  • Gastrointestinal Agents
  • TNF protein, human
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab